Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

out CYT003-QbG10

CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the ImmunodrugTM QbG10 which is comprised of the virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed to induce a potent Th1 type immune response in order to suppress an “allergic” Th2 type immune response. As initial clinical observations indicate, CYT003-QbG10 could thereby act by an allergen-independent mechanism of action so that it has potential as a causal and disease-modifying treatment for a broad range of different allergic diseases. CYT003-QbG10 is currently being studied in several clinical trials for the treatment of allergic rhinitis, asthma and atopic dermatitis.

About allergic diseases

Allergy as a whole is a multi-faceted disease and clinically manifests in various allergic disorders including allergic rhinitis, asthma, atopic dermatitis and food hypersensitivity. It is an exaggerated reaction by the patient’s immune system to a normally harmless substance such as various environmental proteins present in pollen, animal excrements, or food. According to the World Health Organization, more than 20% of the world population suffers from allergic diseases (WHO, 2002).

Seasonal allergic rhinitis due to grass pollen (commonly known as hay fever) is very common and affects 15-20% of the European population (WHO Europe, 2003). Three general approaches are commonly being pursued to relieve the symptoms of allergic diseases: avoidance of the allergen, prescription of medication that targets disease symptoms, and conventional immunotherapy, also known as desensitization. The latter is the only disease-modifying treatment available, however, it is applicable only for some defined allergies, is time-consuming (3-5 years) and inconvenient for the patients. T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/27/2008)...ionally Recognized Pediatric Heart Center at The C...s for Community to Complete Range of Care and ...Recruited Pediatric Cardiology Team Treats Every H...ewswire/ -- The Children,s Hospital at,Montefiore ...c heart,transplantation to the Bronx, following th...
(Date:8/26/2008)...SALEM, Ore., Aug. 26 /- The Oregon To...ity Care Customer Service Training Program,(Q Care...gon Q Care is a training program created to suppor...anced employee education. By emphasizing,the impor...ll equip,employees with tools and resources to bet...
(Date:8/26/2008)...INDIANAPOLIS, Aug. 26 /- Semafore Pha...Seventh International Congress on Targeted,Therapi...al antiangiogenic,activity of vascular-targeted PI... VEGF and Bv8 signaling., PI3K is part of a very ...as been shown to play a major role in cancer. Stud...
(Date:8/26/2008)...Study finds most patients can drive safely six wee...Aug. 26 /PRNewswire-USNewswire/ -- Six weeks follo...e so low that they are able to,get back behind the...gust,2008 issue of The Journal of Bone and Joint S...ergency brake time response in patients who underw...
Breaking Medicine Technology:Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Oregon Tourism Commission Unveils New Online Customer Service Training Program 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Braking After Bunion Surgery 2Braking After Bunion Surgery 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 1Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 5MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 1MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 2MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 1CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 4Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 1Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 2
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ty Massey Cancer Center have discovered a process ...cules containing platinum, which causes HIV and ca...the researchers to develop new drugs to fight HIV ...argeting proteins known as zinc fingers. In the M...
...at funds for wheelchair service from NHS has not r...ildren are losing out their hope due to lack of a ...wheelchair with most basic parts, was given due to...sh Me Around!’, highlights. Thus it calls for Gove...
...n (NBA) have entered into a partnership to support.... // The campaign, 'Unite for Children, Unite aga.../AIDS on children as well as impeding further spre...e know that our sport, indeed all sports, has an e...
...hetamine-like stimulant has a calming effect on ch...er (ADHD) // . A new study undertaken on rats, se...ly used to treat ADHD, appears to work by tweaking...acted by any stimuli from the outside world. The s...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: